DC-specific Ythdf1 loss increased type I IFN production, enhanced cross-priming, and potentiated CD8+ killing, improving the efficacy of radiation and combined radiotherapy plus anti-PD-L1 in multiple murine cancers; a prototype DC vaccine built from Ythdf1-deficient DCs amplified these effects (53). The gene discussed is CD8A; the disease is cancer.